UF startup Axogen has entered into a $200 million agreement to acquire BioCircuit Technologies, adding its FDA-approved NerveTape technology for sutureless peripheral nerve repair.
Under the terms of the agreement, Axogen will acquire BioCircuit for total consideration of $200 million in cash at closing, subject to customary adjustments for cash, indebtedness, transaction expenses and net working capital. At closing, $1.0 million of the estimated merger consideration will be withheld pending determination of the post-closing purchase price adjustment. The transaction is expected to close in the fourth quarter of 2026, subject to satisfaction of customary closing conditions, including completion of the spin-out of BioCircuit’s electronics research and development business.
Read more about Axogen Enters Into Definitive Agreement To Acquire BioCircuit Technologies.
